Antifungal drugs combinations: a patent review 2000-2015

References

• Kathiravan MK, Salakeb AB, Chotheb AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem. 2012;20:5678–5698.
   PubMed Web of Science ®Google Scholar
• Darius AJ, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 2014;22:120–127.
   PubMed Web of Science ®Google Scholar
• Kavanagh K. Fungi: biology and applications. West Sussex, UK: John Wiley & Sons; 2011.
   Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–1111.
   PubMed Web of Science ®Google Scholar
• Vincent J, Rello J, Marshall E, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009;302:2323–2329.
   PubMed Web of Science ®Google Scholar
• Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14:5–24.
   PubMed Web of Science ®Google Scholar
• Brown G, Denning D, Gow N, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.
   PubMed Web of Science ®Google Scholar
• Saravolatz L, Ostrosky-Zeichner L, Marr K, et al. Amphotericin B: time for a new “gold standard”. Clin Infect Dis. 2003;37:415–425.
   PubMed Web of Science ®Google Scholar
• Watt K, Manzoni P, Cohen-Wolkowiez M, et al. Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug. 2013;14:193–202.
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Sheehan D, Hitchcock C, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;8:163–194.
   Google Scholar
• Santo RD. Recent patents in antifungal agent discovery. Expert Opin Ther Patents. 2008;18:275–292.
   Web of Science ®Google Scholar
• Denning D, Echinocandin antifungal drugs. Lancet. 2003;362:1142–1151.
   PubMed Web of Science ®Google Scholar
• Graybill J. Editorial response: can we agree on the treatment of candidiasis?. Clin Infect Dis. 1997; 25:60–62.
   PubMed Web of Science ®Google Scholar
• Odds F. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents. 1996;6:145–147.
   PubMed Web of Science ®Google Scholar
• Zonios D, Bennett J. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29:198–210.
   PubMed Web of Science ®Google Scholar
• Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423.
   PubMed Web of Science ®Google Scholar
• Carrillo-Muñoz A, Finquelievich J, Tur-Tur C, et al. Combination antifungal therapy: a strategy for the management of invasive fungal infections. Rev Esp Quimioter. 2014;27:141–158.
   PubMed Web of Science ®Google Scholar
• Te Dorsthorst D, Verweij P, Meis J, et al. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother. 2004;48:2007–2013.
   PubMed Web of Science ®Google Scholar
• Te Dorsthorst D, Verweij P, Meletiadis J, et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother. 2002;46:2982–2989.
   PubMed Web of Science ®Google Scholar
• Afeltra J, Vitale R, Mouton J, et al. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 2004;48:1335–1343.
   PubMed Web of Science ®Google Scholar
• Lorian V. Antibiotics in laboratory medicine. Philadelphia, USA: Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Kontoyiannis D, Lewis R. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359:1135–1144.
   PubMed Web of Science ®Google Scholar
• Lewis R, Kontoyiannis D. Rationale for combination antifungal therapy. Suppl Pharmacother. 2001;21:149S–164S.
   PubMed Web of Science ®Google Scholar
• Berenbaum M. What is synergy? Pharmacol Rev. 1989;41:93–141.
   PubMed Web of Science ®Google Scholar
• Boucher A, Tam V. Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis. 2006;55:319–325.
   PubMed Web of Science ®Google Scholar
• Tan Y, Clewell H, Campbell J, et al. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment. Int J Env Res Public Health. 2011;8:1613–1630.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Combinations of antifungal agents in therapy–what value are they? J Antimicrob Chemother. 2004;54:854–869.
   PubMed Web of Science ®Google Scholar
• Martinez-Irujo J, Villahermosa M, Alberdi E, et al. A checkerboard method to evaluate interactions between drugs. Biochem Pharmacol. 1996;51:635–644.
   PubMed Web of Science ®Google Scholar
• Hirasawa M, Takada K. Multiple effects of green tea catechins on the antifungal activity of antimycotics against C. albicans. J Antimicrob Chemother. 2004;53:225–229.
   PubMed Web of Science ®Google Scholar
• Butassi E, Svetaz L, Ivancovich J, et al. Synergistic mutual potentiation of antifungal activity of Zuccagnia punctata Cav. and Larrea nitida Cav. extracts in clinical isolates of Candida albicans and Candida glabrata. Phytomedicine. 2015;22:666–678.
   PubMed Web of Science ®Google Scholar
• Chou T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693–715.
   PubMed Web of Science ®Google Scholar
• Soltani R, Khalili H, Shafiee F. Double-disk synergy test for detection of synergistic effect between antibiotics against nosocomial strains of Staphylococcus aureus. J Res Pharm Pract. 2012;1:21–24.
   PubMedGoogle Scholar
• Kiraz N, Dag I, Yamac M, et al. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, e-test, and disk diffusion methods. Antimicrob Agents Chemother. 2010;54:2244–2247.
   PubMed Web of Science ®Google Scholar
• Odds F. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1–1.
   Web of Science ®Google Scholar
• Schelz Z, Molnar J, Hohmann J. Antimicrobial and antiplasmid activities of essential oils. Fitoterapia. 2006;77:279–285.
   PubMed Web of Science ®Google Scholar
• Loewe S. The problem of synergism and antagonism of combined drugs. Arzneim-Forsch. 1953;3:285–290.
   PubMed Web of Science ®Google Scholar
• Williamson E. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8:401–409.
   PubMed Web of Science ®Google Scholar
• White R, Burgess D, Manduru M, et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40:1914–1918.
   PubMed Web of Science ®Google Scholar
• Merlin J. Concepts of synergism and antagonism. Anticancer Res. 1993;14:2315–2319.
   Web of Science ®Google Scholar
• Greco W, Bravo G, Parsons J. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47:331–385.
   PubMed Web of Science ®Google Scholar
• Tallarida R. Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001;298:865–872.
   PubMed Web of Science ®Google Scholar
• Boik J, Newman R, Boik R. Quantifying synergism/antagonism using nonlinear mixed effects modeling: a simulation study. Stat Med. 2008;27:1040–1061.
   PubMed Web of Science ®Google Scholar
• Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg. 1984;22:27–55.
   PubMedGoogle Scholar
• Astellas Pharma Inc. Therapeutic combination of a pneumocandin derivative and an antifungal agent. US7375081B2. 2008.
   Google Scholar
• Arai M, Tomoda H, Okuda T, et al. Funicone-related compounds, potentiators of antifungal miconazole activity, produced by Talaromyces flavus FKI-0076. J Antibiot. 2002;55:172–180.
   PubMed Web of Science ®Google Scholar
• The Kitasato Institute. Substance FKI-0076 and process for producing the same. US6790968B1. 2004; also published as WO2001066537A1 (2001).
   Google Scholar
• Novartis AG Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator. US6919317. 2005; also published as US20030100517A1 (2003), CA2399971A1 (2001), CA2399971C (2009), CN1400909A (2003), CN100400103C (2008), DE60101213D1 (2003), DE60101213T2 (2004), EP1255564A2 (2002), EP1255564B1 (2003), WO2001060345A2 (2001), WO2001060345A3 (2002).
   Google Scholar
• Arai T, Suenaga T, Koyama Y, et al. Ascomycin, an antifungal antibiotic. J Antibiot. 1962;15:231–232.
   PubMed Web of Science ®Google Scholar
• Bulusu M, Baumann K, Stuetz A. Progress in the chemistry of organic natural products. Vienna, Austria: Springer Vienna; 2011.
   Google Scholar
• Kullberg BJ, Oude Lashof AM, Netea MG. Design of efficacy trials of cytokines in combination with antifungal drugs. Clin Infect Dis. 2004;39:S218–S223.
   PubMed Web of Science ®Google Scholar
• Kolman A. Activity of epothilones. Curr Opin Investig Drugs. 2005;6:616–622.
   PubMedGoogle Scholar
• Courchesne W, Hejchman E, Maciejewska D, et al. Antifungal compounds. US20090270496. 2012; also published as US 20090270496 (2009).
   Google Scholar
• Courchesne W. Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther. 2002;300:195–199.
   PubMed Web of Science ®Google Scholar
• Hejchman E, Ostrowska K, Maciejewska D, et al. Synthesis and antifungal activity of derivatives of 2-and 3-benzofurancarboxylic acids. J Pharmacol Exp Ther. 2012;343:380–388.
   PubMed Web of Science ®Google Scholar
• Theravance Inc. Use of echinocandin antifungal agent in combination with a glycopeptide antibacterial agent. US2005/0026819A1. 2005; also published as DE602004010915T2 (2008), US7452861B2 (2008), EP1654036B1 (2007), US7902148 (2008), US20090221470 (2009), WO2005018743A1 (2005).
   Google Scholar
• Theravance Inc. Use of polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent. US2004/0242505A1. 2004; also published as EP1641480A1 (2006), US7521418B2 (2009), US20090215674 (2009), WO2004110473A1 (2004).
   Google Scholar
• Paratek Pharmaceuticals Inc. Substituted tetracycline compounds as synergistic antifungal agents. US7045507B2. 2006; also published as CA2440757A1 (2002), EP1381372A2 (2004), US7960366 (2011), US20030166585 (2003), US20050070510 (2005), US20110245501 (2011), WO2002072031A2 (2002), WO2002072031A3 (2003).
   Google Scholar
• Birch M, Sibley G, Law D, et al. Antifungal combination therapy. US2011/0183969A1. 2011; also published as CA2725445A1 (2009), CN102105170A (2011), EP2303329A1 (2011), WO2009144473A1 (2009).
   Google Scholar
• Janssen Pharmaceutica. Compositions containing an antifungal and a cationic agent. US6207142B1. 2001; also published as CA2272366C (2006), CN1165287C (2004), DE69806577D1 (2004), EP0963195B1 (2002), US6514490 (2003), US20010006981 (2001).
   Google Scholar
• Janssen Pharmaceutica. Compositions containing an antifungal and a phospholipid. US6916479B2. 2005; also published as CN1155359C (2004), DE69806916T2 (2003), EP0975312B1 (2002), US2002/0058059 (2002).
   Google Scholar
• Pierard-Franchimont C, Pierard G, Arrese J, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202:171–176.
   PubMed Web of Science ®Google Scholar
• Kemijski Inštitut. The combination of antifungal compound and modifier of proton homeostasis for destroying or growth inhibition and reproduction of fungi. WO2011119119A2. 2011.
   Google Scholar
• Hemenway C, Dolinski K, Cardenas M, et al. Vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H (+)-ATPase assembly. Genetics. 1195;141:833–844.
   Google Scholar
• Benčina M, Bagar T, Lah L, et al. A comparative genomic analysis of calcium and proton signaling/homeostasis in Aspergillus species. Fungal Genet Biol. 2009;46:S93–S104.
   PubMed Web of Science ®Google Scholar
• Kemijski Inštitut. Pharmaceutical combination of acetylsalicylic acid and antifungal compound for destroying or growth inhibition and reproduction of fungi. WO2011115585A1. 2011.
   Google Scholar
• Neutec Pharma Plc. Treatment of fungal infections with polyene or beta glucan synthase inhibitors antifungals combined with anti-hsp90 antibodies. US2008/0181884A1. 2008; also published as CN1420786A (2003), DE60128893T2 (2007), EP1267925B8 (2007), US20030180285A1 (2003), WO2001076627A8 (2008).
   Google Scholar
• Matthews R, Burnie J, Howat D, et al. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology. 1991;74:20–24.
   PubMed Web of Science ®Google Scholar
• Matthews R, Burnie J. The role of hsp90 in fungal infection. Immunol Today. 1992;13:345–348.
   PubMedGoogle Scholar
• Neutec Pharma Plc. Treatment of fungal infections. US20080095778A1. 2008; also published as CA2564137A1 (2005), CN1946424A (2007), DE602005013197D1 (2005), EP1737488B1 (2007), EP2039369A1 (2009), EP2044954A1 (2009), US7785571 (2010), WO2005102386A1 (2005).
   Google Scholar
• Cornell Research Foundation, Inc. Combinations of fungal cell wall degrading enzyme and fungal cell membrane affecting compound. US6512166B1. 2003; also published as EP0886677A1 (1998), WO1997032973A1 (1997).
   Google Scholar
• Richer DL. Synergism–a patent view. Pestic Sci. 1987;19:309–315.
   Google Scholar
• Hisamitsu Pharmaceutical Co. External preparation for athlete’s foot treatment. US8664224B2. 2014; also published as DE602004029465D1 (2005), EP1637132B1 (2005), US 8664224 B2 (2014), US20070099932 (2007), US20090099202 (2009), US20110269794 (2009), WO 2005/000287 (2005).
   Google Scholar
• Farmo-Nat Ltd. Synergistic herbal extracts. US006027716A. 2000.
   Google Scholar
• British herbal pharmacopeia. Exeter: British Herbal Medicine Association; 1996.
   Google Scholar
• Bradley P. British herbal compendium. A handbook of scientific information on widely used plant drugs. Bournemouth, Dorset: British Herbal Medicine Association and produced by its Scientific Committee; 1992.
   Google Scholar
• Board of Trustees University of Arkansas. Anti-biofilm compositions and methods for using. US2012/0088671A1. 2012; also published as US8741855B2 (2014), EP2624702A4 (2013), US20120088671A1 (2012), US20140271777A1 (2014), WO2012048119A2 (2012), WO2012048119A3 (2012).
   Google Scholar
• Noe C, Noe-Letschnig M Use of combination preparations comprising antifungal agents. U.S. Patent Application 14/044532; also published as US8815925B2 . 2014, US20140030312A1 (2014), CA2651726A1 (2007), CN101484162A (2009), EP2018164A2 (2009), US8552042B2 (2013), US20090208558A1 (2009), WO2007131253A3 (2008).
   Google Scholar
• Klotz S, Drutz D, Harrison J, et al. Adherence and penetration of vascular endothelium by Candida yeasts. Infect Immun. 1983;42:374–384.
   PubMed Web of Science ®Google Scholar
• Oblon, Spivak, Mcclelland, Maier & Neustadt, RC. Antifungal combination therapy. US2004/0023858. 2004; also published as WO 2002/013846 A3 (2004), EP1317277A2 (2004).
   Google Scholar
• Balamayooran G, Batra S, Theivanthiran B, et al. Intrapulmonary G-CSF rescues neutrophil recruitment to the lung and neutrophil release to blood in Gram-negative bacterial infection in MCP-1−/− mice. J Immunol. 2012;189:5849–5859.
   PubMed Web of Science ®Google Scholar
• Penederm Inc. Antifungal/steroid topical compositions. US6075056. 2000; also published as US6075056 (2000), WO2000/053186A1 (2000).
   Google Scholar
• Rosen T, Schell B, Orengo I. Anti‐inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788–792.
   PubMed Web of Science ®Google Scholar
• Schäcke H, Döcke W, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23–43.
   PubMed Web of Science ®Google Scholar
• Al Hasan M, Fitzgerald S, Saoudian M, et al. Dermatology for the practicing allergist: Tinea pedis and its complications. Cma. 2004;2:5.
   Google Scholar
• Narishetty S, Panchagnula R. Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J Control Release. 2004;95:367–379.
   PubMed Web of Science ®Google Scholar
• Cokol M, Chua H, Tasan M, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7:544.
   PubMed Web of Science ®Google Scholar
• Browdy and Neimark P.L.L.C. Kit for treating skin infection. WO2007113830A3. 2009; also published as US20100159035A1 (2010), U.S. Patent Application 12/296280.
   Google Scholar
• Shi TW, Zhang JA, Zhang XW, et al. Combination treatment of oral terbinafine with topical terbinafineand 10% urea ointment in hyperkeratotic type Tinea pedis. Mycoses. 2014;57:560–564.
   PubMed Web of Science ®Google Scholar
• Pennie & Edmons LLP. Pharmaceutical compositions and methods for managing dermatological conditions. US20030007939A1. 2003.
   Google Scholar
• Axiomedic Ltd. Absorbable solid compositions for topical treatment of oral mucosal disorders. US7943169B2. 2011; also published as US20030003140A1 (2003), US20110244039A1 (2011), EP1236466A1 (2002), EP1236466B1 (2011), EP2324821A1 (2011).
   Google Scholar
• Chen L, Yue Q, Zhang X, et al. Genomics-driven discovery of the pneumocandin biosynthetic gene cluster in the fungus Glarea lozoyensis. BMC Genomics. 2013;14:339.
   PubMed Web of Science ®Google Scholar
• Hashimoto S. Micafungin: a sulfated echinocandin. J Antibiot. 2009;62:27–35.
   PubMed Web of Science ®Google Scholar
• Vazquez J, Sobel J. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215–222.
   PubMed Web of Science ®Google Scholar
• Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
   PubMed Web of Science ®Google Scholar
• Bozic I, Reiter J, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2:e00747.
   PubMed Web of Science ®Google Scholar
• Day J, Chau T, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–1302.
   PubMed Web of Science ®Google Scholar
• Belanger E, Yang E, Forrest G. Combination antifungal therapy: when, where, and why. Curr Clin Microbiol Rep. 2015;2:67–75.
   Google Scholar
• Candoni A, Caira M, Cesaro S, et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study. Mycoses. 2014;57:342–350.
   PubMed Web of Science ®Google Scholar